Glyphosate: Bayer allocates $ 2 billion for future cancer claims

Bayer will pay $ XNUMX billion to meet future claims related to a new class action

Don't store avocado like this: it's dangerous

Bayer will pay $ XNUMX billion to meet future claims related to a new class action, the litigation filed before the Northern California District Court. The latter has been following the events related to the glyphosate and its effects on health.

In fact, therefore, Bayer has set aside a treasury and has just signed a $ 2 billion agreement with the lawyers to resolve future lawsuits related to the fact that its roundup, glyphosate, has caused cancer.

Under the proposed plan, Bayer will provide $ 2 billion over a 4-year period in compensation and to cover health care and diagnostics. Future applicants could receive up to $ 200.000.

An impressive figure that is added to the 10 billion dollars, 9,6 to be precise, paid out by Bayer in June to resolve over 100.000 lawsuits in the United States.

Bayer inherited the litigation after the $ 63 billion acquisition of Monsanto in 2018. According to the company, decades of studies have shown that its products including glyphosate are safe for human use. But for years now, the causes have been multiplying by sick people who claim that Roundup and other glyphosate-based herbicides are linked to non-Hodgkin's lymphoma.

Bayer today announced a formal agreement with plaintiffs' class counsel for a class action action designed to handle and resolve future Roundup ™ cases. The plaintiffs' attorney filed a motion for preliminary approval of the settlement with United States District Court Judge Vince Chhabria for the Northern District of California, who chairs the Monsanto Roundup ™ Multiple District Litigation. Under the agreement, the company would have committed to pay up to US $ 2 billion to support the requests, ”Bayer said in a press release released yesterday.

The agreement will therefore cover future claims made by individuals diagnosed with non-Hodgkin's lymphoma and exposed to glyphosate prior to diagnosis. It also includes benefits for people who have been exposed to Roundup and will develop cancer in the future. Now the word is for US District Court Judge Vince Chhabria who has dealt with the glyphosate and cancer legal disputes several times and who will have to approve the agreement.

The fact remains that glyphosate will remain on the market. Bayer has agreed to seek permission from the US Environmental Protection Agency to provide a reference on the labels so that consumers can find scientific studies on the herbicide.

"Consistent with Bayer's recent actions to provide greater transparency and access to glyphosate studies, the company will also require permission from the Environmental Protection Agency (EPA) to add a reference link on the labels of its glyphosate products. glyphosate which will provide consumers with access to scientific studies and information that the company is authorized to disclose or that is in the public domain, ”Bayer explains.

To read the details of the agreement click here

Sources of reference: Bayer, Reuters

  • READ also:
  • Bayer-Monsanto finally convicted of poisoning a farmer with Lasso herbicide
  • Glyphosate: Bayer to pay $ 10,5 billion to close 95 lawsuits against Roundup accused of causing cancer
  • Bayer and Basf defeated in court, maxi compensation is underway: historic ruling on Dicamba
  • "Glyphosate is a determinant of cancer." Bayer defeated again in court
add a comment of Glyphosate: Bayer allocates $ 2 billion for future cancer claims
Comment sent successfully! We will review it in the next few hours.